Groups ask Congress not to regulate CMS drug decisions

A coalition of consumer groups are asking Congress not to countermand a recent decision by CMS to limit Medicare coverage for anemia medication use. They've written a letter asking Reps. Anna Eshoo (D-CA) and Mike Rogers (R-MI) to reconsider their Congressional Review Act joint resolution, a measure which would require CMS to reverse the anemia decision.

The coalition members, which include the U.S. Public Interest Research Group, the Center for Science in the Public Interest and Consumers Union, suggest that regardless of the merits in this case, getting Congress involved in medical decision-making would "set a terrible precedent." Their position is that once you open up such decisions to the lobbying process, Congress would be under terrible pressure to demand that CMS spend money in ways that suit their donors' interests. (Coalition members seem especially concerned about the demands of medical product makers and medical specialty organizations.)

To find out more about the debate:
- read this Kaiser Daily Health Policy Report item

Related Articles:
Dialysis firms defend anemia drug use along ethnic lines. Report
FDA group recommends anemia drug limits. Report
Anemia drug rebates challenged. Report
Regulators question anemia drugs. Report
New study points to danger of anemia drug. Report

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.